Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 9,236 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 9,236 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $27.03, for a total transaction of $249,649.08. Following the completion of the sale, the president owned 913,004 shares in the company, valued at approximately $24,678,498.12. This trade represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Arcus Biosciences Trading Up 2.0%

NYSE RCUS opened at $28.74 on Thursday. The firm’s 50-day moving average is $24.53 and its two-hundred day moving average is $22.92. Arcus Biosciences, Inc. has a 12 month low of $7.91 and a 12 month high of $29.85. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04. The stock has a market capitalization of $3.61 billion, a P/E ratio of -9.04 and a beta of 0.85.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The company had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.48 million. During the same period last year, the business earned ($1.14) EPS. The company’s quarterly revenue was down 39.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Arcus Biosciences, Inc. will post -3.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on RCUS shares. Citigroup lifted their target price on shares of Arcus Biosciences from $44.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Monday, April 20th. Lifesci Capital began coverage on Arcus Biosciences in a research report on Thursday, June 4th. They set an “outperform” rating and a $46.00 price target for the company. Truist Financial began coverage on Arcus Biosciences in a research note on Monday, May 18th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Leerink Partners set a $47.00 price objective on Arcus Biosciences in a report on Monday, April 20th. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.10.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Hantz Financial Services Inc. grew its holdings in shares of Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after purchasing an additional 881 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in Arcus Biosciences during the 4th quarter worth approximately $39,000. KBC Group NV purchased a new position in Arcus Biosciences in the 1st quarter valued at approximately $50,000. Strs Ohio purchased a new position in Arcus Biosciences in the 1st quarter valued at approximately $67,000. Finally, Tower Research Capital LLC TRC boosted its position in Arcus Biosciences by 184.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock valued at $69,000 after buying an additional 5,476 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.